| 1. |
|
|
| 2. |
- Dahlen, E., et al.
(författare)
-
Defined daily doses in pediatric dosing- a theoretical example
- 2023
-
Ingår i: Pharmacology Research & Perspectives. - : Wiley. - 2052-1707. ; 11:2
-
Tidskriftsartikel (refereegranskat)abstract
- A defined daily dose for children (cDDD) taking body weight into account, was proposed as a better measure of drug utilization in children than the World Health Organization's DDD. There is no global definition of DDDs for children, and it is unclear which standard doses should be used for children when conducting drug utilization studies. We used doses according to the authorized medical product information and body weight according to national pediatric growth curves to calculate theoretical cDDD for three common medicines in children in a Swedish setting. These examples demonstrate that the concept of cDDD may not be optimal for drug utilization studies in children, especially not for younger children and when dosing is done according to weight is crucial. Validation of cDDD in real-world data is warranted. When conducting pediatric drug utilization studies, accessibility to individual-level data on body weight and age combined with dosing information is needed.
|
|
| 3. |
- Kimland, E. E., et al.
(författare)
-
Melatonin Prescription in Children and Adolescents in Relation to Body Weight and Age
- 2023
-
Ingår i: Pharmaceuticals. - : MDPI AG. - 1424-8247. ; 16:3
-
Tidskriftsartikel (refereegranskat)abstract
- The prescription of melatonin to children and adolescents has increased dramatically in Sweden and internationally during the last ten years. In the present study we aimed to evaluate the prescribed melatonin dose in relation to body weight and age in children. The population-based BMI Epidemiology Study Gothenburg cohort has weight available from school health care records, and information on melatonin prescription through linkage with high-quality national registers. We included prescriptions of melatonin to individuals below 18 years of age where a weight measurement not earlier than three months before, or later than six months after the dispensing date, was available (n = 1554). Similar maximum doses were prescribed to individuals with overweight orobesity as to individuals with normal weight, and to individuals below and above 9 years of age. Age and weight only explained a marginal part of the variance in maximum dose, but were inversely associated and explained a substantial part of the variance in maximum dose per kg. As a result, individuals overweight or with obesity, or age above 9 years, received lower maximum dose per kg of body weight, compared with individuals with normal weight or below 9 years of age. Thus, the prescribed melatonin dose to individuals under 18 years of age is not primarily informed by body weight or age, resulting in substantial differences in prescribed dose per kg of body weight across BMI and age distribution.
|
|
| 4. |
|
|
| 5. |
- Brink, B., et al.
(författare)
-
Ovanligt fall av läkemedelsbiverkan : Cefotaximutlöst konfusion hos patient med njursvikt [Unusual side effect of cefotaxime: Confusion in a patient with renal failure]
- 2003
-
Ingår i: Läkartidningen. - : Läkartidningen AB. - 0023-7205 .- 1652-7518. ; 100:28-29, s. 2370-2371
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Third-generation cephalosporins in general have few adverse effects and cefotaxime (Claforan) particularly is considered to be a good choice because of the favourable side effect profile. In patients with severe renal failure there have been reports of confusion and psychosis. The manufacturer therefore recommends that half the ordinary dose should be given to patients with severe renal failure. Half the ordinary dose can still be too much. We describe a patient in hemodialysis who reacted with a reversible encephalopathy with psychosis in spite of reduced doses of cefotaxime. The plasma concentration of cefotaxime was high and the reaction was diagnosed as a dose dependent side effect.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
